GB Sciences, Inc., a plant-based research and biopharmaceutical drug development company. The company offers cannabis inspired medicines and complex therapeutic mixtures for the prescription drug market. Its intellectual property covers a range of medical conditions and programs in pre-clinical animal stage for Parkinson’s disease, neuropathic pain, chronic pain, cytokine release syndrome, stress/anxiety/depression, and cardiovascular therapeutic programs. The company was formerly known as Growblox Sciences, Inc. and changed its name to GB Sciences, Inc. in October 2016. GB Sciences, Inc. is based in Las Vegas, Nevada.
Name | Title | Since | Age |
|---|---|---|---|
| Andrea Small-Howard | CEO, Interim CFO, Chairman of Scientific Advisory Board, CSO, President & Chairman of the Board | 2024 | 57 |
| Helen Turner | Member of Scientific Advisory Board | 2014 | - |
| Zoltan Mari | Member of Scientific Advisory Board | 2018 | - |
| Norbert E. Kaminski | Member of Scientific Advisory Board | - | - |
| Carlos F. Rios-Bedoya | Member of Scientific Advisory Board | - | - |
| Alexander Stokes | Member of Scientific Advisory Board | - | - |